PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER

摘要

The specification generally relates to compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, where R¹, A¹, A² and A³ have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent DNA-PK mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating DNA-PK mediated disease, including cancer, using such compounds and salts.